Posizioni attive di Douglas Eby
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Cambridge Science Corp.
 Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - | - |
| Amministratore Delegato | - | - | |
| Presidente | - | - | |
KYTTARO Ltd.
 KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | Direttore/Membro del Consiglio | - | - |
| Amministratore Delegato | - | - |
Storia della carriera di Douglas Eby
Statistiche
Distribuzione geografica
| Stati Uniti | 2 |
| Regno Unito | 2 |
Posizioni
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| President | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Cambridge Science Corp.
Cambridge Science Corp. BiotechnologyHealth Technology Cambridge Science Corp. engages in investing in the medicine. It also engages in improving patient lives through the acceleration of translational research and develops internal drug development programs. The firm finances and manages biotech companies commercializing novel technologies developed in the labs and the research institutions. The company was founded in 2017 and is headquartered in Cambridge, MA. | Health Technology |
KYTTARO Ltd.
KYTTARO Ltd. BiotechnologyHealth Technology Kyttaro Ltd. develops monoclonal antibodies for potential treatment of atherosclerotic cardiovascular diseases. The company is based in Oxford, UK. The British company was founded in 2021. The CEO is Douglas Eby. | Health Technology |
- Borsa valori
- Insiders
- Douglas Eby
- Esperienza
